Release Date: 2024-02-12

Gene Therapy in Hereditary Diseases

Mahir Binici (Author), Ilyas YüCel (Author)

Release Date: 2024-02-12

Inherited diseases are caused by mutations or genetic changes in an individual’s DNA, leading to familial inheritance patterns. These diseases can be categorized into monogenic, multifactorial, and chromosomal diseases. Understanding the genetic basis of these diseases is crucial for identifying their causes and developing genetic counseling services. Common hereditary diseases, such as cystic fibrosis and [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inGene Therapy
    First Page129
    Last Page152
    DOIhttps://doi.org/10.69860/nobel.9786053358824.9
    Page Count24
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    Inherited diseases are caused by mutations or genetic changes in an individual’s DNA, leading to familial inheritance patterns. These diseases can be categorized into monogenic, multifactorial, and chromosomal diseases. Understanding the genetic basis of these diseases is crucial for identifying their causes and developing genetic counseling services. Common hereditary diseases, such as cystic fibrosis and Huntington’s disease, result from specific genetic disorders and exhibit various symptoms, which can guide early diagnosis and treatment. Knowledge of genetic risk factors and inheritance models is essential for comprehending disease susceptibility and aiding in prevention, diagnosis, and treatment. Genetic counseling and testing play vital roles in managing inherited diseases by assessing risks and facilitating early detection and personalized treatment plans.

    Mahir Binici (Author)
    Dicle University
    https://orcid.org/0000-0003-1039-9361
    3Mahir Binici works as a research assistant at Dicle University Faculty of Medicine. He completed his undergraduate studies in Biology at Dicle University Faculty of Science and obtained his master’s and doctoral degrees in Medical Biology and Genetics from the Health Sciences Institute of the same university. He began his academic career as a research assistant in 2013 and has been involved in various genetic research projects. His research primarily focuses on pediatric genetic disorders, and he has published articles in numerous national and international scientific journals. Additionally, he has presented his work at several national and international conferences and has received various awards for his contributions to the field.

    Ilyas YüCel (Author)
    Assistant Professor, Dicle University
    https://orcid.org/0000-0002-4446-0469
    3Ilyas Yücel has been serving as an Assistant Professor at Dicle University Faculty of Medicine in the Department of Medical Biology since 2023. He has a distinguished academic background, having earned his Ph.D. in Medical Biology from Dicle University in 2019. His doctoral research focused on cytogenetic analysis and gene mutations in patients with preliminary diagnoses of sex anomalies. Dr. Yücel has been actively involved in numerous research projects and has published several papers in international peer-reviewed journals. His work primarily revolves around genetic disorders and chromosomal abnormalities, making significant contributions to the field of medical genetics. In addition to his current role, Dr. Yücel has gained valuable international experience. From June 13 to June 17, 2016, he served as a Research Assistant at Universitats Klinikum Freiburg, a prestigious university hospital in Germany. Earlier, he was a Guest Research Assistant at Instituto Hispalanse de Pediatria in Spain from June 25 to September 23, 2012. During the same period, he also participated in the Erasmus Internship program under Educacion y Cultura Leonardo da Vinci, funded by the European Union. Beyond his research, Dr. Yücel is dedicated to teaching and mentoring students, helping to shape the next generation of medical professionals and researchers. His commitment to both education and research highlights his pivotal role in advancing medical science and genetics.

    • Tüysüz B. Akraba Evlilikleri ve Kalıtsal Hastalıklar. Türk Pediatri Arşivi. 2000; 35:3.

    • Trımble BK, Doughty JH. The amount of hereditary disease in human populations. Annals of human genetics. 1974;38.2:199-223.

    • Masoumı A et al. Developments in the management of autosomal dominant polycystic kidney disease. Therapeutics and clinical risk management. 2008;4.2:393-407.

    • Sozen MA. Obezite ve Obezitenin Genetigi. Kocatepe Tıp Dergisi. 2006;7.3:1-11.

    • Taıvalsaarı A. On the notion of inheritance. ACM Computing Surveys (CSUR). 1996;28.3:438-479.

    • Genç A, Ekin K, and Zeynep R. Çocuklarda Genetik Danışma.

    • Aydemir H, Ayata MK. Sağlık Bilimleri Fakültesi Öğrencilerinin Genetik Hastalıklar, Prenatal Testler ve Genetik Konusundaki Bilgi Düzeyleri. Kırşehir Ahi Evran Üniversitesi Sağlık Bilimleri Dergisi. 2022;6.3:174-183.

    • Sparks TN, Dugoff L. How to choose a test for prenatal genetic diagnosis: a practical overview. American Journal of Obstetrics and Gynecology. 2023;228.2:178-186.

    • Walpole IR et al. Evaluation of a project to enhance knowledge of hereditary diseases and management. Journal of medical genetics. 1997;34.10:831-837.

    • Bockenstedt PL. Management of hereditary hypercoagulable disorders. ASH Education Program Book. 2006;2006.1:444-449.

    • Tauscher S. Genetik teknolojisinin siyasi ve etik sınırları: genetiği yönetmek. Uluslararası Politik Araştırmalar Dergisi. 2015;1.1:1-12.

    • Aykan EB, Fidancı BE. Pediatri Hemşireliğinde Genetik/Genomik. Turkish Journal of Family Medicine and Primary Care. 2021;15.4:895-905.

    • Grıll K, Rosén A. Healthcare professionals’ responsibility for informing relatives at risk of hereditary disease. Journal of medical ethics. 2021;47.12:e12-e12.

    • Grandjean P, Sorsa M. Ethical aspects of genetic predisposition to environmentally- related disease. Science of the total environment. 1996;184.1-2:37-43.

    • Bove CM, FRY ST, Macdonald DJ. Presymptomatic and predisposition genetic testing: ethical and social considerations. In: Seminars in oncology nursing. WB Saunders. 1997;p.135-140.

    • Wırth T, Parker N, Ylä-Herttuala S. History of gene therapy. Gene. 2013;525.2:162- 169.

    • Mountaın A. Gene therapy: the first decade. Trends in biotechnology. 2000;18.3:119- 128.

    • Kaufmann KB et al. Gene therapy on the move. EMBO molecular medicine. 2013;5.11:1642-1661.

    • Schmıtt TM, Ragnarsson GB, Greenberg PD. T cell receptor gene therapy for cancer. Human gene therapy. 2009;20.11:1240-1248.

    • Lundstrom K. Viral vectors in gene therapy. Diseases. 2018;6.2:42.

    • Zhang B. CRISPR/Cas gene therapy. Journal of Cellular Physiology. 2021;236.4:2459- 2481.

    • Ibraheem D, Elaıssarı A, Fessı H. Gene therapy and DNA delivery systems. International journal of pharmaceutics. 2014;459.1-2:70-83.

    • Chuah MKL, Collen D, Vandendrıessche T. Biosafety of adenoviral vectors. Current gene therapy. 2003;3.6:527-543.

    • Mehıer-Humbert S, Guy RH. Physical methods for gene transfer: improving the kinetics of gene delivery into cells. Advanced drug delivery reviews. 2005;57.5:733-753.

    • Capecchı MR. High efficiency transformation by direct microinjection of DNA into cultured mammalian cells. Cell. 1980;22.2:479-488.

    • Reılly A, Chehade L, Kothary R. Curing SMA: Are we there yet?. Gene therapy. 2023;30.1-2:8-17.

    • The Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/ fda-approves-first-drug-spinal-muscular-atrophy (Access Date: 15.11.2023).

    • Lejman J et al. Gene therapy in ALS and SMA: advances, challenges and perspectives. International Journal of Molecular Sciences. 2023;24.2:1130.

    • The Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/ fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal- muscular-atrophy-rare-disease (Access Date: 15.11.2023).

    • Jonckheere AI et al. Metachromatic leukodystrophy: To screen or not to screen?. European Journal of Paediatric Neurology 2023.

    • The European Medicines Agency https://www.ema.europa.eu/en/medicines/human/ EPAR/libmeldy (Access Date: 15.11.2023).

    • Venugopal V, Pavlakıs S. Duchenne muscular dystrophy. StatPearls. 2023.

    • The Food and Drug Administration. https://www.fda.gov/news-events/ press-announcements/fda-approves-first-gene-therapy-treatment-certain-patients- duchenne-muscular-dystrophy (Access Date: 15.11.2023).

    • Soroka AB et al. Gene Therapy Approaches for the Treatment of Hemophilia B. International Journal of Molecular Sciences. 2023;24.13:10766.

    • The Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/ fda-approves-first-gene-therapy-treat-adults-hemophilia-b (Access Date: 15.11.2023).

    • Malvası M et al. Gene Therapy in Hereditary Retinal Dystrophies: The Usefulness of Diagnostic Tools in Candidate Patient Selections. International Journal of Molecular Sciences. 2023;24.18:13756.

    • The Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/ fda-approves-novel-gene-therapy-treat-patients-rare-form-inheritedvision- loss (Access Date: 15.11.2023).

    • Khan A et al. Revolutionary breakthrough: FDA approves VYJUVEK™, the first topical gene therapy for dystrophic epidermolysis bullosa. Annals of Medicine and Surgery. 2023;10.1097.

    • The Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/ fda-approves-first-topical-gene-therapy-treatment-wounds-patients- dystrophic-epidermolysis-bullosa (Access Date: 15.11.2023).

    • Chrıstakopoulos GE et al. Gene therapy and gene editing for β-thalassemia. Hematology/ Oncology Clinics. 2023;37.2:433-447.

    • The Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/ fda-approves-first-cell-based-gene-therapy-treat-adult-and-pediatricpatients- beta-thalassemia-who (Access Date: 15.11.2023).

    • Balasubramanıan S, Aggarwal P, Sharma S. Lipoprotein Lipase Deficiency. In: Stat- Pearls [Internet]. StatPearls Publishing, 2023.

    • The European Medicines Agency 43- https://www.ema.europa.eu/en/documents/ product-information/glybera-epar-product-information_en.pdf (Access Date: 15.11.2023).

    • Mullıgan RC. The basic science of gene therapy. Science; 1993;260.5110:926-932.

    • Cavazzana-Calvo M, Thrasher A, Mavılıo F. The future of gene therapy. Nature. 2004;427.6977:779-781.

    • Gallo-Penn AM et al. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. Blood, The Journal of the American Society of Hematology. 2001;97.1:107-113.

    • Lechardeur D et al. Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. Gene therapy. 1999;6.4:482-497.

    • Gordon JW et al. Genetic transformation of mouse embryos by microinjection of purified DNA. Proceedings of the National Academy of Sciences. 1980;77.12:7380- 7384.

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!